Neurotoxicity Screening of New Psychoactive Substances (NPS): Effects on Neuronal Activity in Rat Cortical Cultures Using Microelectrode Arrays (MEA)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. -
2015-02 Toxicology Rapid Testing Panel
SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O. -
3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden. -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
10.30.19 Didactic
STIMULANTS PART II Michael H. Baumann, Ph.D. Designer Drug Research Unit (DDRU), Intramural Research Program, NIDA, NIH Baltimore, MD 21224 Chronology of Stimulant Misuse 1. 2000s: Methamphetamine 2. 2010s: Bath Salts 3. Summary 2 Topics Covered for Each Substance Chemistry Formulations and Methods of Use Pharmacokinetics and Metabolism Desired and Adverse Effects Chronic and Withdrawal Effects Neurobiology Treatments 2000s: Methamphetamine Methamphetamine, a synthetic stimulant 5 Formulations and Methods of Use Methamphetamine (i.e., Ice or Crystal) Smoking using pipes Methamphetamine HCl Intravenous injection of solutions using needle and syringe Intranasal snorting of crystals Pharmacokinetics and Metabolism Pharmacokinetics Smoked and intravenous drugs reach brain within seconds Intranasal drug reaches brain within minutes Much longer half-life than cocaine Metabolism N-demethylation to form amphetamine (bioactive) Hydroxylation to form inactive metabolites Desired Effects Enhanced Mood and Euphoria Increased Attention and Alertness Decreased Need for Sleep Appetite Suppression Sexual Arousal Adverse Effects Psychosis Arrhythmias, Palpitations, Heart Attack Hypertension, Stroke Hyperthermia, Rhabdomyolysis Multisystem Organ Failure 11 www.facesofmeth.us. “METH Mouth” 12 Molecular Sites of Action SLC6 Monoamine Transporters Dopamine transporter (DAT) Norepinephrine transporter (NET) 5-HT transporter (SERT) Other sites Vesicular Monoamine Transporter 2 (VMAT2) Trace amine-associated receptors (TAAR1) -
Assessment of Combined Toxicity of Heavy Metals from Industrial Wastewaters on Photobacterium Phosphoreum T3S
Appl Water Sci DOI 10.1007/s13201-016-0385-4 ORIGINAL ARTICLE Assessment of combined toxicity of heavy metals from industrial wastewaters on Photobacterium phosphoreum T3S 1,2 1 2 1 2 BibiSaima Zeb • Zheng Ping • Qaisar Mahmood • Qiu Lin • Arshid Pervez • 2 2 2 Muhammad Irshad • Muhammad Bilal • Zulfiqar Ahmad Bhatti • Shahida Shaheen2 Received: 19 May 2015 / Accepted: 19 January 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract This research work is focusing on the toxicities Introduction of heavy metals of industrial origin to anaerobic digestion of the industrial wastewater. Photobacterium phospho- The presence of heavy metals in excess amounts inter- reum T3S was used as an indicator organism. The acute feres with the beneficial uses of water because of the toxicities of heavy metals on P. phosphoreum T3S were toxicity of heavy metals and the biomagnification effect assessed during 15-min half inhibitory concentration brought on by its accumulation on ecology (Chang et al. (IC50) as indicator at pH 5.5–6. Toxicity assays involved 2006; Altas 2009). During recent times, heavy metals the assessment of multicomponent mixtures using TU and were focus of attention owing to their hazardous nature MTI approaches. The results of individual toxicity indi- and subsequent toxicity studies. Various workers have cated that the toxicity of Cd, Cu and Pb on P. phospho- assessed the combined toxicity of heavy metals (Su reum increased with increasing concentrations and there et al. 2012;Quetal.2013; Mochida et al. 2006). It has was a linear correlation. The 15-min IC50 values of Cd, Cu been argued that the effects caused by combinations of and Pb were 0.537, 1.905 and 1.231 mg/L, respectively, various heavy metals may be more threatening and and their toxic order was Cd [ Pb [ Cu. -
Introduction
Guidance for Assay Development & HTS March 2007 Version 5 Section I: Introduction Introduction Copyright © 2005, Eli Lilly and Company and the National Institutes of Health Chemical Genomics Center. All Rights Reserved. For more information, please review the Privacy Policy and Site Usage and Agreement. Table of Contents A. INTRODUCTION This document is written to provide guidance to investigators that are interested in developing assays useful for the evaluation of compound collections to identify chemical probes that modulate the activity of biological targets. Originally written as a guide for therapeutic projects teams within a major pharmaceutical company, this manual has been adapted to provide guidelines for: a. Identifying potential assay formats compatible with High Throughput Screen (HTS), and Structure Activity Relationship (SAR) b. Developing optimal assay reagents c. Optimizing assay protocol with respect to sensitivity, dynamic range, signal intensity and stability d. Adopting screening assays to automation and scale up in microtiter plate formats e. Statistical validation of the assay performance parameters f. Secondary follow up assays for chemical probe validation and SAR refinement g. Data standards to be followed in reporting screening and SAR assay results. General definition of biological assays This manual is intended to provide guidance in the area of biological assay development, screening and compound evaluation. In this regard an assay is defined by a set of reagents that produce a detectable signal allowing a biological process to be quantified. In general, the quality of an assay is defined by the robustness and reproducibility of this signal in the absence of any test compounds or in the presence of inactive compounds. -
AGENDA Friday, September 9, 2016 7:00 A.M
Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted. -
An Online Tool for Calculating and Mining Dose–Response Data Nicholas A
Clark et al. BMC Cancer (2017) 17:698 DOI 10.1186/s12885-017-3689-3 SOFTWARE Open Access GRcalculator: an online tool for calculating and mining dose–response data Nicholas A. Clark1†, Marc Hafner2†, Michal Kouril3, Elizabeth H. Williams2, Jeremy L. Muhlich2, Marcin Pilarczyk1, Mario Niepel2, Peter K. Sorger2 and Mario Medvedovic1* Abstract Background: Quantifying the response of cell lines to drugs or other perturbagens is the cornerstone of pre-clinical drug development and pharmacogenomics as well as a means to study factors that contribute to sensitivity and resistance. In dividing cells, traditional metrics derived from dose–response curves such as IC50, AUC, and Emax, are confounded by the number of cell divisions taking place during the assay, which varies widely for biological and experimental reasons. Hafner et al. (Nat Meth 13:521–627, 2016) recently proposed an alternative way to quantify drug response, normalized growth rate (GR) inhibition, that is robust to such confounders. Adoption of the GR method is expected to improve the reproducibility of dose–response assays and the reliability of pharmacogenomic associations (Hafner et al. 500–502, 2017). Results: We describe here an interactive website (www.grcalculator.org) for calculation, analysis, and visualization of dose–response data using the GR approach and for comparison of GR and traditional metrics. Data can be user-supplied or derived from published datasets. The web tools are implemented in the form of three integrated Shiny applications (grcalculator, grbrowser, and grtutorial) deployed through a Shiny server. Intuitive graphical user interfaces (GUIs) allow for interactive analysis and visualization of data. The Shiny applications make use of two R packages (shinyLi and GRmetrics) specifically developed for this purpose. -
Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved. -
Written Witness Statement for U.S. Sentencing Commission's Public
STATEMENT OF TERRENCE L. BOOS, PH.D. SECTION CHIEF DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION and CASSANDRA PRIOLEAU, PH.D. DRUG SCIENCE SPECIALIST DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION - - - BEFORE THE UNITED STATES SENTENCING COMMISSION - - - HEARING ON SENTENCING POLICY FOR SYNTHETIC DRUGS - - - OCTOBER 4, 2017 WASHINGTON, D.C. 1 Introduction New Psychoactive Substances (NPS) are substances trafficked as alternatives to well- studied controlled substances of abuse. NPS have demonstrated adverse health effects such as paranoia, psychosis, and seizures to name a few. Cathinones, cannabinoids, and fentanyl-related substances are the most common NPS drug classes encountered on the illicit drug market, all with negative consequences for the user to include serious injury and death. Our early experience saw substances being introduced from past research efforts in an attempt to evade controls. This has evolved to NPS manufacturers structurally altering substances at a rapid pace with unknown outcomes to targeting specific user populations. These substances represent an unprecedented level of diversity and consequences. Due to clandestine manufacture and unscrupulous trafficking, the user is at great risk. A misconception exists that these substances carry a lower risk of harm In reality, published reports from law enforcement, emergency room physicians and scientists, accompanied with autopsies from medical examiners, have clearly demonstrated the harmful and potentially deadly consequences of using synthetic cathinones. These substances are introduced in an attempt to circumvent drug controls and the recent flood of NPS remains a challenge for law enforcement and public health. The United Nations Office on Drugs and Crime reported over 700 NPS encountered.1 The manufacturers and traffickers make minor changes in the chemical structure of known substances of abuse and maintain the pharmacological effect. -
Lack of Correlation Between in Vitro and in Vivo Studies on the Inhibitory Effects Of
pharmaceutics Article Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (-)-Sophoranone on CYP2C9 Is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (-)-Sophoranone 1, 2,3, 3 3 3 Yu Fen Zheng y, Soo Hyeon Bae y , Zhouchi Huang , Soon Uk Chae , Seong Jun Jo , Hyung Joon Shim 3, Chae Bin Lee 3, Doyun Kim 3,4, Hunseung Yoo 4 and Soo Kyung Bae 3,* 1 School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 639 Longmian Road, Jiangning District, Nanjing 211198, China; [email protected] 2 Q-fitter, Inc., Seoul 06578, Korea; sh.bae@qfitter.com 3 College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University, Korea, Bucheon 14662, Korea; [email protected] (Z.H.); [email protected] (S.U.C.); [email protected] (S.J.J.); [email protected] (H.J.S.); [email protected] (C.B.L.); [email protected] (D.K.) 4 Life Science R&D Center, SK Chemicals, 310 Pangyo-ro, Sungnam 13494, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-2164-4054 These authors contributed equally to this work. y Received: 8 March 2020; Accepted: 5 April 2020; Published: 7 April 2020 Abstract: (-)-Sophoranone (SPN) is a bioactive component of Sophora tonkinensis with various pharmacological activities. This study aims to evaluate its in vitro and in vivo inhibitory potential against the nine major CYP enzymes. Of the nine tested CYPs, it exerted the strongest inhibitory effect on CYP2C9-mediated tolbutamide 4-hydroxylation with the lowest IC50 (Ki) value of 0.966 0.149 µM (0.503 0.0383 µM), in a competitive manner.